MedTrace Logo

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

NCT06493019 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-03-23

No results posted yet for this study

Summary

A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).

Conditions

Interventions

DRUG

Pembrolizumab

Chemoradiation Pembrolizumab 200mg IV

DRUG

Paclitaxel

Paclitaxel 50 mg/m\^2 IV

DRUG

Carboplatin

Carboplatin AUC 2 IV

RADIATION

Radiation

Delivered as per institutional standards

DRUG

Pembrolizumab

Maintenance Pembrolizumab 400mg IV

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    collaborator OTHER

  • Dustin Deming

    lead OTHER

Principal Investigators

  • Dustin Deming, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2027-04-15
Completion
2029-04-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06493019 on ClinicalTrials.gov